REG-4basebio Plc: Director Dealing

4BasebioAnnouncement

11/02/2026 16:00

11 February 2026

 

 

4basebio PLC

 

("4basebio" or the "Company")

 

Director Dealings

 

Cambridge, UK,                                                              
11 February 2026                               –                    
4basebio PLC                     (AIM: 4BB), an innovation driven
biotechnology company enabling and accelerating development of advanced
therapy medicinal products (ATMPs) through its high performant GMP-grade
synthetic DNA products, announces that on 10 February 2026 it was informed
that certain Non-executive Directors of the Company made the following
purchases in ordinary shares in the capital of the Company through the market.

 

Further details are set out in the Notification of Dealing Form below.

 Director / PCA            Number of Ordinary Shares Acquired  Purchase Price (Aggregated) (p)  Shareholding Following Acquisition  Shareholding Following Acquisition as a Percentage of Issued Share Capital  
 Dr. Heikki Lanckriet      3,000                               575.82                           1,122,688                           7.23%                                                                       
 Mr Hansjörg Plaggemars*   1,000                               585.00                           7,667†                              0.05%†                                                                      
                                                                                                                                                                                                                
 * Purchase was made by Mr Plaggemars, on behalf of his wife.   † Aggregate shareholding of Mr Plaggemars and persons closely associated with him.                                                              

 

The 3,000 and 1,000 additional shares purchased represent approximately 0.02
per cent. and 0.01 per cent. of the Company's issued share capital,
respectively.

 

The issued share capital of the Company comprises 15,538,518 ordinary shares.

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310.

 

For further enquiries, please contact:

 

 4basebio PLC                                                                                                             +44 (0)12 2396 7943  
 Dr Amy Walker, CEO                                                                                                                            
                                                                                                                                               
 Cairn Financial Advisers LLP (Nominated Adviser  )                                                                       +44 (0)20 7213 0880  
 Jo Turner / Sandy Jamieson / Ed Downes                                                                                                        
                                                                                                                                               
 Cavendish Capital Markets Limited (Joint Broker)                                                                         +44 (0)20 7220 0500  
 Geoff Nash / Nigel Birks                                                                                                                      
                                                                                                                                               
 RBC Capital Markets (Joint Broker)                                                                                       +44 (0)20 7653 4000  
 Kathryn Deegan / Matthew Coakes     ICR Healthcare (Media and Investor Relations)   Mary-Jane Elliott / Jessica Hodgson  +44 (0)203 707 5700  

 

Notes to Editors

 

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

 

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.                      Although the directors believe their
expectations are based on reasonable assumptions, any statements about future
outlook may be influenced by factors that could cause actual outcomes and
results to be materially different.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1   Details of the persons discharging managerial responsibilities / person closely associated                                                                                                            
 a)  Name                                                                                               1)  Dr. Heikki Lanckriet  2)  Mr Hansjörg Plaggemars                                               
 2   Reason for the notification                                                                                                                                                                           
 a)  Position/Status                                                                                    1)  Non-executive Director  2)  Non-executive Director                                             
 b)  Initial notification/ Amendment                                                                    Initial notification                                                                               
 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                         
 a)  Name                                                                                               4basebio plc                                                                                       
 b)  LEI                                                                                                213800E2DX9EAIUNCB30                                                                               
 4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted     
 a)  Description of the financial  instrument, type of  instrument    Identification code               Ordinary Shares                                                                                    
                                                                                                           ISIN: GB00BMCLYF79                                                                              
 b)  Nature of the transaction                                                                          Acquisition of ordinary shares                                                                     
 c)  Price(s) and volume(s)                                                                                                                                                                                
     Price(s)                                                                                           Volume(s)                                                                                          
 1)  575.82p                                                                                            3,000                                                                                              
 2)  585.00p                                                                                            1,000                                                                                              
 d)  Aggregated information    -       Aggregated volume      -       Aggregated Price                  1)  3,000  2)  1,000    1)  575.82p  2)  585.00p                                                   
 e)  Date of transaction                                                                                10 February 2026                                                                                   
 f)  Place of transaction                                                                               London Stock Exchange                                                                              

 



Copyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved